已收录 268921 条政策
 政策提纲
  • 暂无提纲
A systematic review of filler agents for aesthetic treatment of HIV facial lipoatrophy (FLA)
[摘要] HIV facial lipoatrophy (FLA) is characterized by facial volume loss. HIV FLA affects the facial contours of the cheeks, temples, and orbits, and is associated with social stigma. Although new highly active antiretroviral therapy medications are associated with less severe FLA, the prevalence of HIV FLA among treated individuals exceeds 50%. The goal of our systematic review is to examine published clinical studies involving the use of filler agents for aesthetic treatment of HIV FLA and to provide evidence-based recommendations based on published efficacy and safety data. A systematic review of the published literature was performed on July 1, 2015, on filler agents for aesthetic treatment of HIV FLA. Based on published studies, poly-L-lactic acid is the only filler agent with grade of recommendation: B. Other reviewed filler agents received grade of recommendation: C or D. Poly-L-lactic acid may be best for treatment over temples and cheeks, whereas calcium hydroxylapatite, with a Food and Drug Administration indication of subdermal implantation, may be best used deeply over bone for focal enhancement. Additional long-term randomized controlled trials are necessary to elucidate the advantages and disadvantages of fillers that have different biophysical properties, in conjunction with cost-effectiveness analysis, for treatment of HIV FLA.
[发布日期] 2015-12-01 [发布机构] 
[效力级别]  [学科分类] 
[关键词] facial volume loss;filler agent;highly active antiretroviral therapy;HIV facial lipoatrophy;HIV lipodystrophy;quality of life [时效性] 
   浏览次数:1      统一登录查看全文      激活码登录查看全文